PROTAC RIPK degrader-6

Cat. No.: HY-111870

CAS No.: 2089205-64-9

Molecular Formula: $C_{43}H_{48}N_6O_{11}S_2$

Molecular Weight: 889

Target: PROTAC; RIP kinase

Pathway: PROTAC; Apoptosis

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (112.49 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.1249 mL	5.6243 mL	11.2486 mL
	5 mM	0.2250 mL	1.1249 mL	2.2497 mL
	10 mM	0.1125 mL	0.5624 mL	1.1249 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 7.5 mg/mL (8.44 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 7.5 mg/mL (8.44 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PROTAC RIPK degrader-6 (example 1) is a PROTAC targeting RIP Kinase degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder[1].

IC_{50} & Target

Cereblon

In Vitro

PROTACs is useful for the targeted degradation of proteins and other polypeptides which on the one end binds to the cereblon and on the other end to the target protein (RIP2 kinase). By bringing the target protein in close proximity to the E3-Ligase, these compounds form a ternary complex leading to polyubiquitination of the target protein inducing its degradation[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. John David Harlin, et al. Compounds for the modulation of rip2 kinase activity. WO2017046036A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA